Abstract
Despite years of international effort, cancer remains a major cause of death in developed countries, claiming more than 500 000 lives per year in the United States alone. Recombinant DNA technology and high throughput screening methods have recently increased the pace of cancer research. In this review, we will examine the impact and contribution of phage display technology to this area of research. As a biological combinatorial system, the strength of phage display lies in its flexibility and its ability to efficiently study protein-protein interactions. The technology has also facilitated the discovery of molecules that have potential roles in the diagnosis and treatment of cancer.
Keywords: Phage Display, protein-protein interactions, glioblastomas, cDNA libraries, immunogenic, anti-ErbB-2 internalising Mab, Melanoma, immunotherapeutic agents, Cytotoxic T lymphocytes, Monoclonal antibody
Current Pharmaceutical Biotechnology
Title: Application of Phage Display Technology to Cancer Research
Volume: 3 Issue: 1
Author(s): Yum L. Yip and Robyn L. Ward
Affiliation:
Keywords: Phage Display, protein-protein interactions, glioblastomas, cDNA libraries, immunogenic, anti-ErbB-2 internalising Mab, Melanoma, immunotherapeutic agents, Cytotoxic T lymphocytes, Monoclonal antibody
Abstract: Despite years of international effort, cancer remains a major cause of death in developed countries, claiming more than 500 000 lives per year in the United States alone. Recombinant DNA technology and high throughput screening methods have recently increased the pace of cancer research. In this review, we will examine the impact and contribution of phage display technology to this area of research. As a biological combinatorial system, the strength of phage display lies in its flexibility and its ability to efficiently study protein-protein interactions. The technology has also facilitated the discovery of molecules that have potential roles in the diagnosis and treatment of cancer.
Export Options
About this article
Cite this article as:
Yip L. Yum and Ward L. Robyn, Application of Phage Display Technology to Cancer Research, Current Pharmaceutical Biotechnology 2002; 3 (1) . https://dx.doi.org/10.2174/1389201023378472
DOI https://dx.doi.org/10.2174/1389201023378472 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiviral Activities of Human Host Defense Peptides
Current Medicinal Chemistry Biological Therapies For Inflammatory Bowel Disease: Research DrivesClinics
Mini-Reviews in Medicinal Chemistry Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes?
Current Women`s Health Reviews Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Concomitant Drug Treatment and Elimination in the RCC-affected Kidneys: Can We Kill Two Birds with One Stone?
Current Drug Metabolism Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Sinonasal Carcinoma: Updated Phenotypic and Molecular Characterization
Current Cancer Therapy Reviews Targeting the EGF/HER Ligand-Receptor System in Cancer
Current Pharmaceutical Design Recent Advance in Polymer Based Microspheric Systems for Controlled Protein and Peptide Delivery
Current Medicinal Chemistry The Design of Amphiphilic Polymeric Micelles of Curcumin for Cancer Management
Current Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets DNA-Binding Properties of Poly(ADP-Ribose) Polymerase: A Target for Anti-Cancer Therapy
Current Drug Targets